MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
Endovascular Treatment of Intracranial Posttraumatic Lesions
Assessing arteriovenous fistulas, dissections, and aneurysms.
By Rosana Ceratto, MD; Jorge Chudyk, MD; Carlos Bleise; and Pedro Lylyk, MD
Endovascular Treatment of Cerebral Aneurysms
Current devices, emerging therapies, and future technology for the management of cerebral aneurysms.
By David Fiorella, MD, PhD; Michael E. Kelly, MD; Raymond D. Turner IV, MD; and Pedro Lylyk, MD
CereVasc eShunt System Studied in Treatment of Patients with NPH
February 26, 2026—CereVasc, Inc. announced results from a prospective, multicenter, single-arm clinical study evaluating the safety and clinical outcomes of the eShunt system in patients with normal pressure hydrocephalus (NPH).
Embolization Therapies
By Barry T. Katzen, MD, Chief Medical Editor
CereVasc Receives IDE Approval for United States Pilot Study of eShunt System to Treat Communicating Hydrocephalus paSAH
August 9, 2022—CereVasc, Inc. announced that the FDA has approved an investigational device exemption (IDE) application to initiate a pilot trial of the company’s eShunt system in patients who develop communicating hydrocephalus post aneurysmal subarachnoid hemorrhage (paSAH).
CereVasc’s eShunt Device Evaluated in FIH Trial for Endovascular Treatment of Communicating Hydrocephalus
December 7, 2021—CereVasc, Inc. announced the publication of a case report detailing the first-in-human (FIH) treatment in a study of the company’s eShunt system, an investigational device intended to treat communicating hydrocephalus (CH).
ETCHES Study of CereVasc eShunt for Communicating Hydrocephalus Completes Enrollment
January 21, 2026—CereVasc, Inc. announced the completion of enrollment in its ETCHES 1 study of the company’s eShunt system for the treatment of communicating hydrocephalus.
CereVasc Receives IDE Approval to Expand Study of Gen2 eShunt System in Patients With NPH
September 18, 2023—CereVasc, Inc. announced that the FDA has approved an investigational device exemption (IDE) supplement to permit the expansion of the study of the company’s second-generation (Gen2) eShunt system in patients with normal pressure hydrocephalus (NPH) to additional study participants and clinical sites.
CereVasc eShunt System’s STRIDE Trial Enrolls First Patient
January 14, 2025—CereVasc, Inc. announced that the first patient was enrolled in the STRIDE clinical trial of the company’s eShunt system to treat patients with normal pressure hydrocephalus (NPH).
Gentuity’s Vis-M High-Frequency OCT Imaging System Directly Visualizes Neurovascular Pathologies in FIH Procedures
January 12, 2023—Gentuity, LLC, a Massachusetts-based imaging and artificial intelligence firm developing intravascular devices, announced the first-in-human (FIH) use of the Vis-M high-frequency optical coherence tomography (HF-OCT) imaging system and probe.
Vascular Trauma
By Claudio Schö,nholz, MD
CereVasc Begins Trial of eShunt System for Communicating Hydrocephalus
February 10, 2021—CereVasc, Inc. announced that the first patient has been treated in a study of the company’s eShunt system, an investigational device intended to treat communicating hydrocephalus (CH).
New Developments in Intravascular Imaging and Sensing Technologies
The current status of the Vis-M HF-OCT neurovascular probe that acquires artifact-free, high-resolution images of the cerebrovasculature and a novel laser angioscopy platform for intravascular imaging from “head to toe.”
With Demetrius Lopes, MD; Matt Gounis, PhD; and Luis Savastano, MD, PhD
Flow Diversion for Intracranial Aneurysm Treatment
How this new technology may expand the types of intracranial aneurysms that can be treated.
By David Fiorella, MD, PhD; Michael Kelly, MD; and Henry Woo, MD
